Plasma Tumor DNA in Breast Oncology
Plasma tumor DNA (ptDNA) is superior to serum for analyzing the DNA shed by tumors into the bloodstream.
SABCS 2016
Can Studying Tumor Ecology Reveal New Paths to Treatment?
Emerging research suggests that tumor development involves much more than mutant clones.
More Work Needed Before Multigene Mutation Testing Ready for Routine Clinical Practice
Circulating free tumor DNA techniques might improve the ability to match tumor mutations to genotype-matched targeted therapies.
Large-scale Analysis of Sequencing Data Confirms Genes That Increase Breast Cancer Risk
BARD1, RAD51D, and MSH6 gene variants increase breast cancer risk.
Tumor-infiltrating Lymphocytes Associated With HER2+ Breast Cancer Survival
Higher tumor-infiltrating lymphocyte (TIL) values in tumor stroma are associated with longer overall survival (OS).
Somatic ER+ Breast Cancer Mutations Predict Worse Patient Outcomes
Gene mutation status is prognostic for postmenopausal women with early-stage estrogen receptor-positive (ER+) breast cancer.
Biomarkers and MammaPrint Status Predict Breast Cancer Response to Veliparib and Carboplatin
Several mechanism-of-action-based biomarkers predict high-risk HER2-negative breast cancer response to combination therapy.
Veliparib Safe in Combination With Carboplatin and Paclitaxel for BRCA1/2-associated Breast Cancer
Adding veliparib to carboplatin and paclitaxel for patients with advanced BRCA mutation-associated breast cancer is safe but did not improve survival.
The Challenges of Treating Triple-negative Breast Cancer
A panel at the 2016 San Antonio Breast Cancer Symposium discussed the state of research and treatment of triple negative breast cancer (TNBC).
Extending Adjuvant Anastrozole to 6 Years After Tamoxifen Does Not Improve Breast Cancer Survival
Extending adjuvant anastrozole therapy from 3 to 6 years after up to 3 years of tamoxifen does not improve breast cancer survival outcomes.
- Loading...
Loading...
Next post in SABCS 2016
Loading... 
Loading...